Invesaro

Stocks Health care IQV

NYSE · Health care

Iqvia Holdings Inc. (IQV)

Iqvia Holdings Inc. brought in $16.6B of revenue over the twelve months to March 31, 2026, up 7.3% from a year earlier. Net income was $1.4B, a net margin of 8.3%. Operating cash flow minus capital spending left $2.1B of free cash flow in fiscal 2025. At March 31, 2026 it held $1.9B in cash against $15.8B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 28, 2026.

Price
$270.37
-1.69% on the day · September 25, 2026
52-week range $154.50 to $277.40
Market cap
$44.5B
Revenue (last 12 months)
$16.6B
+7.3% year on year
Net margin
8.3%
P/E
34.5
on FY2025 diluted EPS

What Iqvia Holdings Inc. does

IQVIA provides clinical research services, healthcare data analytics, and consulting services to pharmaceutical, biotechnology, and medical device companies. The company manages clinical trials for new drugs and licenses healthcare market data and commercial software to life sciences organizations. Its shares trade on NYSE under the ticker IQV.

Revenue and profit by year

Revenue
FY18: $10.4B $10.4B FY18FY19: $11.1B $11.1B FY19FY20: $11.4B $11.4B FY20FY21: $13.9B $13.9B FY21FY22: $14.4B $14.4B FY22FY23: $15B $15B FY23FY24: $15.4B $15.4B FY24FY25: $16.3B $16.3B FY25
Net income
FY18: $259M $259M FY18FY19: $191M $191M FY19FY20: $279M $279M FY20FY21: $966M $966M FY21FY22: $1.1B $1.1B FY22FY23: $1.4B $1.4B FY23FY24: $1.4B $1.4B FY24FY25: $1.4B $1.4B FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$16.3B$2.2B$1.4B$7.84$2.1B
2024$15.4B$2.2B$1.4B$7.49$2.1B
2023$15B$2B$1.4B$7.29$1.5B
2022$14.4B$1.8B$1.1B$5.72$1.6B
2021$13.9B$1.4B$966M$4.95$2.3B
2020$11.4B$731M$279M$1.43$1.3B

Latest SEC filings

What Iqvia Holdings Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 23, 2026
  2. September 9, 2026
  3. July 28, 2026
    Quarterly report 10-Q · period to June 30, 2026
  4. July 28, 2026
  5. June 11, 2026
  6. June 4, 2026
  7. June 3, 2026
  8. May 7, 2026
  9. May 5, 2026
    Quarterly report 10-Q · period to March 31, 2026
  10. May 5, 2026

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 4, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about IQV

What does Iqvia Holdings Inc. do?

IQVIA provides clinical research services, healthcare data analytics, and consulting services to pharmaceutical, biotechnology, and medical device companies. The company manages clinical trials for new drugs and licenses healthcare market data and commercial software to life sciences organizations. Its shares trade on NYSE under the ticker IQV.

Is Iqvia Holdings Inc. profitable?

Yes. Over the twelve months to March 31, 2026 it reported net income of $1.4B on revenue of $16.6B, a net margin of 8.3%.

How much revenue does Iqvia Holdings Inc. make?

Over the twelve months to March 31, 2026 Iqvia Holdings Inc. reported revenue of $16.6B. That is 7.3% more than a year earlier.

When did Iqvia Holdings Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on July 28, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the material agreement from September 23, 2026.

Similar companies

Follow IQV

Get an email when Iqvia Holdings Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow IQV: get an email when it files

Where the numbers come from

Financial figures are the values Iqvia Holdings Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.